Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
D. Leeming (Herlev, Denmark), J. Thorlacius-Usssing (Herlev, Denmark), J. Sand (Herlev, Denmark), T. Manon-Jensen (Herlev, Denmark), S. Sun (Herlev, Denmark), M. Karsdal (Herlev, Denmark), N. Villumsen (Herlev, Denmark). Type XIX collagen quantified in serum targeting the anti-tumorigenic NC1 domain is elevated in early and late stage lung carcinoma patients and COPD. 1736

Member's Comments

No comment yet.

Related content which might interest you: A novel serum biomarker of type XXVIII collagen turnover is elevated in lung cancer but not in COPD Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020 A neo-epitope of collagen type VII (C7) is elevated in serum of patients with COPD and SSC Source: International Congress 2016 – Exploring mechanisms in health and disease Year: 2016 Serum type III procollagen peptide in idiopathic pulmonary fibrosis: peptide levels and anti-fibrosis therapy Source: Eur Respir J 2005; 26: Suppl. 49, 30s Year: 2005 The influence of roflumilast on the IV-type collagen level in patients with III stage COPD Source: Annual Congress 2012 - Lung injury and repair: reactive oxygen species and beyond Year: 2012 Serum levels of a MMP-12 generated type IV collagen fragment is elevated in COPD and IPF patients Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases Year: 2013 Type V collagen and endothelial apoptosis interface in non small cell lung cancer has impact on prognosis Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008 Microparticle-associated tissue factor activity is increased in late stage lung cancer Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer Year: 2011 Late stage of experimental pulmonary fibrosis is modulated by collagen V Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 NSCLC stage IV Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 The role of cell lines in modelling the type II pneumocyte in interstitial lung disease Source: Virtual Congress 2020 – Human ex vivo models of interstitial lung disease Year: 2020 Analysis of prognostic factors in patients with stage IIIB, IV non-small cell lung cancer Source: Annual Congress 2010 - Staging of lung cancer Year: 2010 Collagen I, III and IV content in airways and lung parenchyma of COPD patients Source: Annual Congress 2010 - Proteases and the matrix Year: 2010 Validity of predictive estimate by physicians of the survival of patients with recently diagnosed stages IIIB and IV non-small cells lung cancer (NSCLC) Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology Year: 2007 Type I and III collagen protein precursors in the airways of smokers and COPD-patients Source: Annual Congress 2008 - Structural remodelling in COPD Year: 2008 Collagen degradation profile in serum of patients with COPD or IPF Source: Annual Congress 2012 - Monitoring of airway diseases: far from the airways Year: 2012 Stage IIIB and stage IV non-small cell lung cancers; responses to treatment and survival durations Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004 MMP-2 expression in lung periphery is related to COPD progression Source: Eur Respir J 2006; 28: Suppl. 50, 550s Year: 2006 Treatment tolerance and survival in elderly patients with stage IV non-small cell lung cancer (NSCLC) Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology Year: 2019 The pronounced high expression of discoidin domain receptor 2 in human interstitial lung diseases Source: ERJ Open Res, 4 (1) 00138-2016; 10.1183/23120541.00138-2016 Year: 2018 Analysis of survival and characteristics of patients with non-small cell lung carcinoma (NSCLC) stage IV depending on molecular markers Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019